BioBlog Weekly oncology

Research Yields New Methods of Attack, Diagnosis, and Mysteries of Breast Cancer

IP Blog | Dave Melin | April 23, 2017

The articles in this week’s BioBlog explore new research and initiatives in breast cancer. Scientists Identify New Way of Attacking Breast Cancer Scientists have discovered a new way to attack breast cancer by blocking a protein that has been shown to increase tumor growth. The Impostor Cell Line That Set Back Breast Cancer Research It […]

Read Full Post »


BioBlog Weekly oncology

Cancer Moonshot, Cancer Funding, Genome Mapping

IP Blog | Dave Melin | April 16, 2017

In this week’s BioBlog, we learn about recent progress in the Cancer Moonshot initiative, potential cuts to cancer research funding, as well as a proposed shift in genome mapping. A Cancer ‘Moonshot’ In this article we learn how Bloomberg–Kimmel Institute for Cancer Immunotherapy is helping Johns Hopkins further their research in immunotherapy. Biden Gives Update on Cancer […]

Read Full Post »


BioBlog Weekly oncology

Cancer Drug Costs and Development

IP Blog | Dave Melin | April 9, 2017

In this week’s BioBlog we examine the process to develop and bring new cancer drugs to market. The new drugs come at high price, creating a lot of debate and chatter on the best way to control and lower these prices. The Cost of Cancer: New Drugs Show Success at a Steep Price Immunotherapy drugs continue […]

Read Full Post »


BioBlog Weekly oncology

IP Blog | Dave Melin | April 2, 2017

This week’s BioBlog features articles about Immunotherapy Biomarkers, Trump Vows to Explode ACA, Cancer and Immunity, the Benefits of Early Palliative Care and more. Diving Deeper Into Cancer Immunotherapy Biomarkers Looking at the future of immunotherapy one main obstacle remains: determining which patients will benefit from it. Affordable Care Act Remains ‘Law of the Land,’ […]

Read Full Post »


BioBlog Weekly oncology

AHCA Pulled, End of Life Models, Biosimilars, MACRA, ASCO Lifting COI Restrictions

IP Blog | Dave Melin | March 26, 2017

In this week’s BioBlog we look at the American Health Care Act being pulled, new research in various end of life models, the use of biosimilars to lower the cost of drug therapy, MACRA implementation, and ASCO removing conflict of interest restrictions on researchers. House Republicans Pull Health Care Bill Since they didn’t have the votes […]

Read Full Post »


BioBlog Weekly oncology

American Health Care Act, Nominations and Confirmations, ASCO Special Awards

IP Blog | Dave Melin | March 19, 2017

In this week’s BioBlog we look at the new details and projections for the American Health Care Act, the confirmation of Seema Verma and the nomination of Dr. Scott Gottlieb for FDA commissioner. ASCO has also announced this year’s recipients of the ASCO Special Awards. CBO: Republican Healthcare Bill Would Reduce Federal Deficit—but Millions Fewer […]

Read Full Post »


BioBlog Weekly oncology

ACA Repeal, CancerLinQ, and State of Cancer Care in America Report

IP Blog | Dave Melin | March 12, 2017

This week’s BioBlog focuses on the newly unveiled bill to repeal and replace Obamacare, a newly formed CancerLinQ ambassadors program, and the upcoming release of the annual State of Cancer in America report. Republicans Finally Ready to Reveal ACA Repeal and Replace Plan but Opposition is Likely This week republicans unveiled their new plan to […]

Read Full Post »


BioBlog Weekly oncology

CancerLinQ, Cancer Moonshot Funding Opportunities, AI, and More

IP Blog | Dave Melin | March 5, 2017

This week’s BioBlog is stocked with current articles from around the web that relate to oncology, big data, and innovative health care. CancerLinQ Partners with Premier Radiation Oncology Society This new partnership promises to bring radiation oncology expertise to help improve cancer care. NCI Announced New Funding Opportunities Related to Cancer Moonshot The National Cancer Institute […]

Read Full Post »


BioBlog Weekly oncology

Drug Costs, Patient-Generated Health Data, ACA Repeal, Multigene Testing, and Cancer Policy

IP Blog | Dave Melin | February 26, 2017

In this week’s BioBlog we look at how difficult it is for cancer patients to afford their medications and the difficult choices they face, the outlook for hospital in the potential ACA repeal and more. Cancer Survivors Skip Prescription Drugs Due to Cost: Study New research shows that cancer patients often skip doses or look […]

Read Full Post »


BioBlog Weekly oncology

Tom Price Confirmed, Humana Exit, Cancer Moonshot, and Cooling Caps

IP Blog | Dave Melin | February 19, 2017

In this week’s BioBlog we look at the confirmation of Tom Price, the exit of Humana in the exchanges, new developments in the Cancer Moonshot initiative, and the use of cooling caps during chemotherapy. ASCO Congratulates Rep. Tom Price on Confirmation as Secretary of Health and Human Services ASCO is looking forward to working with […]

Read Full Post »


BioBlog Weekly oncology

Reducing Drug Costs, Value-Based Care, and Precision Medicine

IP Blog | Dave Melin | February 12, 2017

In this week’s BioBlog we learn about new and continued efforts being made to reduce drug costs, the continued effort toward value-based care and evaluating treatment effectiveness, as well as the obstacle of the high costs of cancer treatment. Report Commissioned by COA Explores “Murky” World of Pharmacy DIR Fees In this article we look […]

Read Full Post »


BioBlog Weekly oncology

Kaput Acquisitions, Cancer Drugs and Quality Measures

IP Blog | Dave Melin | February 5, 2017

This week’s BioBlog outlines the Anthem Cigna deal,  several articles on increased prices of cancer drugs, and suggestions to improve oncology quality measures. Anthem’s Cigna Deal Is All but Kaput, and That May Be Good News for Blues Plans It seems likely that Anthem’s plan to buy Cigna will not be approved, since it would substantially […]

Read Full Post »


BioBlog Weekly oncology

2017 Proving to Be Full of Changes in Cancer Healthcare

IP Blog | Dave Melin | January 29, 2017

This week’s BioBlog contains a few of the many articles that share the changes, innovations, and forecasts that 2017 is heralding. ION Solutions to Provide Patient Engagement Technology to its Nationwide Oncology Network with HealthGrid This article reports on how HealthGrid technology will allow ION members who dispense and administer oral chemotherapy to connect with patients […]

Read Full Post »


BioBlog Weekly oncology

Drug Formulary, Quality Reporting, Prescription Database, Pharmaceutical Companies Sold, and Drug Rebates

IP Blog | Dave Melin | January 22, 2017

In this week’s BioBlog we look at a new drug formulary, the new MACRA fact sheets, and the development of a universal prescription database. Also in the news the sale of pharmaceutical companies, and drug rebates that health plan providers receive. New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials This week […]

Read Full Post »


BioBlog Weekly oncology

Cancer Moonshot, Drug Pricing, ACA Repeal, and Pharmaceutical Company Acquisitions

IP Blog | Dave Melin | January 15, 2017

This week’s BioBlog focuses on VP Biden’s plans after he leaves office, pharmaceutical company acquisitions, the drive to repeal and replace the ACA, and the continued battle over drug costs. At San Francisco Event, Biden Vows to Make Fighting Cancer His Cause At an event in San Francisco, VP Biden reiterated his intentions to continue his […]

Read Full Post »


BioBlog Weekly oncology

Obamacare Repeal, Drug Prices, Cancer Research Advances

IP Blog | Dave Melin | January 8, 2017

In this week’s Bio Blog we look at the road to repealing and replacing ObamaCare, research advances in how cancer spreads, and Biden’s plans to continue working on cancer issues when he leaves office. U.S. Republican Senator Introduces Obamacare Repeal Resolution The Senate budget committee chairman, Mike Enzi, introduced a resolution to repeal Obamacare on the […]

Read Full Post »


BioBlog Weekly oncology

Cancer Research, Clinical Trials, and Drug Costs

IP Blog | Dave Melin | January 2, 2017

In this week’s BioBlog we look at advancements in cancer research and clinical trials, and the high costs of cancer drugs limiting the availability of it to patients. TSU Cancer Research Aims to Reduce Disparities A current research project at Tennessee State University is studying what creates higher cancer rates in specific groups compared to […]

Read Full Post »


BioBlog Weekly oncology

Cancer Drug Costs, Part B Demo, and Value-Base Care

IP Blog | Dave Melin | December 26, 2016

In this week’s BioBlog we look at the cost and regulation of cancer drugs, the outlook for value-based care in the new administration, and the Part B Demo. In Closely Watched Case, Colombia Cuts the Price of a Novartis Cancer Drug by 44 Percent The Colombian government moved to reduce the cost of the cancer […]

Read Full Post »


BioBlog Weekly oncology

21st Century Cures Act, Scalp Cooling Technology, and Looking Forward to 2017

IP Blog | Dave Melin | December 18, 2016

This week’s BioBlog contains articles about the 21st Century Cures Act that was signed this past week,  scalp cooling technology seeks FDA clearance, 2017 industry projections, and more. The 21st Century Cures Act — A View from the NIH This article from the New England Journal of Medicine focuses on aspects of the Cures Act that are […]

Read Full Post »


BioBlog Weekly oncology

Innovation in the Home Care Model, Urgent Care, and Big Data

IP Blog | Dave Melin | December 11, 2016

This week’s BioBlog is stocked full of current articles on innovative home care models, urgent care just for cancer patients, and much more. Cancer Medical Home Model Cuts Costs, Improves Care One doctor’s medical home model, known as Come Home, grew out of her observation that every time she sent cancer patients to the hospital, they would […]

Read Full Post »


BioBlog Weekly oncology

Health Agency Nominations, Health Policy Changes, and Cancer Treatment Costs

IP Blog | Dave Melin | December 4, 2016

This week’s BioBlog focuses on Trump’s health agency nominations, cancer treatment costs, expected health insurance company profitability in 2017, and expected health policy changes for the upcoming legislative session. Medicare Beneficiaries Face High Out-of-Pocket Costs for Cancer Treatment Johns Hopkins reports that individuals on medicare who don’t have a supplemental plan pay huge out of pocket costs. Donald […]

Read Full Post »


BioBlog Weekly oncology

Value-Based Care, Quality Payment Program, Research Funding, Telomeres, and the ROCKET Trial

IP Blog | Dave Melin | November 27, 2016

This week’s BioBlog focuses on the the continued push toward Value-Based Care even with expected changes to the ACA, physician readiness to comply with the Quality Payment Program, cancer research funding, telomere research, and cancer treatment trial complications. End of ACA Won’t Stop March Toward Value-Based Care, Experts Say PRWeb reports that they expect Trump to […]

Read Full Post »


BioBlog Weekly oncology

Value-Based Care, Drug Costs, Gene Therapy, and Research Funding

IP Blog | Dave Melin | November 20, 2016

This week’s BioBlog focuses on continued efforts toward Value-Based Care, expensive cancer drug costs, the impact that Donald Trump’s presidency will have on funding and research, and using gene therapy to help alleviate harmful affects of cancer treatment. Florida Cancer Care Provider Starts New Bundle With United Health In their effort to continue moving toward a value-based care system, […]

Read Full Post »


clinical pathways doctor

Clinical Pathways Spotlight

IP Blog | Dave Melin | November 16, 2016

This week in health care trends, our oncology clinical pathways spotlight includes articles on the possible future of hospital care, new research and information around breast cancer, and a stem cell transplant startup partners with Harvard Tech. Healthcare in 2030: Goodbye Hospital, Hello Home-Spital Melanie Walker, Senior Adviser to the President, World Bank envisions the […]

Read Full Post »


BioBlog Weekly oncology

Election Impact, Moonshot, and Big Pharma

IP Blog | Dave Melin | November 13, 2016

This week’s BioBlog focuses on the impact the election results will have on cancer research and the Cancer Moonshot, UHG’s national ACO, and Big Pharma drug pricing. Biopharma Stocks Jump as Americans Vote for Trump In this article Fierce Biotech reports the surprising impact that the election results had on biopharma stocks. The Fate of Cancer […]

Read Full Post »


cancer supportive care hands

Cancer Supportive Care Spotlight

IP Blog | Dave Melin | November 9, 2016

This week in health care trends, our cancer supportive care spotlight features videos and resources for physicians, providers and clinical staff, and; palliative care from one patient’s perspective. CAPC Videos & Podcasts The Center to Advance Palliative Care (CAPC) hosts an abundance of resources for providers of supportive care. Types of Cancer-Related Nausea and Vomiting […]

Read Full Post »


BioBlog Weekly oncology

Shortage of Oncologists, Changes in Payment Models, Palliative Care, and Preparing for 2017

IP Blog | Dave Melin | November 6, 2016

This week’s BioBlog focuses on the need for oncologists outpacing the supply, payment models, changing the scope of palliative care, and more. A Shortage of Oncologists In 2014, the Journal of Oncology Practice predicted that demand (for oncologists) will grow by about 40 percent, whereas supply may grow only about 25 percent by the year 2025. […]

Read Full Post »


data stethoscope

Big Data in Oncology Spotlight

IP Blog | Dave Melin | November 2, 2016

This week in health care trends, our big data in oncology spotlight includes articles that inspire us with new ways of using information as an employee benefit, exploring health frontiers, expanding practice offerings, and building new partnerships around the world. IBM’s Latest Employee Benefit: Medical Advice from Watson Ebn reports in this article that IBM […]

Read Full Post »


BioBlog Weekly oncology

Payer Summit, Payment Adjustments, Payment Models and More

IP Blog | Dave Melin | October 30, 2016

This week’s BioBlog focuses on strategies for payers, payment adjustments, contradictions to popular notions, and more. Strategies for OCM Implementation at the COA Payer Summit This article from AJMC.com provides preliminary responses to the following questions: What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? […]

Read Full Post »


Oncology Patient Advocacy Spotlight

IP Blog | Dave Melin | October 26, 2016

In this week’s Oncology Spotlight we learn about Patient Advocacy from the perspective of a cancer survivor and a terminally ill woman, from two different care centers, and an update on the Cancer Moonshot Initiative. Cancer Research Advocacy: Progress With a Side of Heartbreak Jamie Holloway, a PhD student in tumor biology and survivor of […]

Read Full Post »